| Period | Net Revenue | Cost of Revenue | Net Profit | EPS |
|---|---|---|---|---|
| FY2022 | 356.85M |
255.9M | 356.85M |
$-1.13 |
| Q32022 |
95.35M
+17.7%
|
69.6M |
-2.33M
+71.9%
|
$-0.04 |
| Q22022 |
81.03M
+12.2%
|
58.34M |
-8.31M
-6.1%
|
$-0.14 |
| Q12022 |
72.22M
|
49.24M |
-7.83M |
$-0.14 |
| FY2021 | 181.12M |
117.14M | -35.72M |
$-0.84 |
| Q42021 |
53.87M
+12.1%
|
36.33M |
-4.88M
-168.2%
|
$-0.09 |
| Q32021 |
48.07M
+17.6%
|
31.39M |
-1.82M
+85.2%
|
$-0.03 |
| Q22021 |
40.87M
+6.7%
|
25.87M |
-12.33M
+26.9%
|
$-0.3 |
| Q12021 |
38.32M
|
23.55M |
-16.87M |
$-0.6 |
| FY2020 | 83.27M |
52.45M | -6.35M |
$-0.45 |
| FY2019 | 31.29M |
19.98M | -26.13M |
$-1.95 |
| FY2018 | 8.75M |
5.64M | -4.53M |
$-0.35 |
| Period | Total Assets | Total Liabilities | Cash & Eq. | Debt | Stock Equity |
|---|---|---|---|---|---|
| FY2022 | 274.74M |
112.71M | 25.08M |
96.6M |
156.35M |
| Q32022 | 309.66M |
107.16M | 18.32M |
63.19M |
195.56M |
| Q22022 | 302.04M |
113.29M | 15M |
60.84M |
181.99M |
| Q12022 | 290.57M |
108.26M | 10.08M |
58.17M |
174.88M |
| FY2021 | 246.22M |
94.21M | 14.01M |
67.7M |
147.21M |
| FY2020 | 69.81M |
58.09M | 7.52M |
65.54M |
10.17M |
| FY2019 | 40.74M |
31.34M | 806k |
28.29M |
9.59M |
| FY2018 | 25.92M |
2.61M | 8.2M |
101.92k |
23.33M |
| Period | Operating CF | Investing CF | Financing CF | Capex | Free Cash Flow |
|---|---|---|---|---|---|
| FY 2022 | 4.5M |
-8.59M | 15.17M |
-9.06M |
-4.56M |
| Q32022 | 44k |
-2.81M | 6.09M |
-2.92M |
-2.87M
+39.8%
|
| Q22022 | -2.24M |
-2.46M | 9.61M |
-2.54M |
-4.77M
-17.3%
|
| Q12022 | -1.58M |
-2.06M | -293k |
-2.49M |
-4.07M
|
| FY2021 | -2.83M |
-28.49M | 37.81M |
-10.71M |
-13.54M |
| FY2020 | 8.85M |
-3.3M | 1.17M |
-2.77M |
6.08M |
| FY2019 | -14.83M |
-16.92M | 24.36M |
-10.41M |
-25.24M |
| FY2018 | -8.78M |
-4.23M | 20.14M |
-4.23M |
-13.01M |
KemPharm, Inc.
Fennec Pharmaceuticals...
Clene Inc.
Savara Inc.
Harvard Bioscience, In...
Compugen Ltd.
NeuroPace, Inc.
Quipt Home Medical Cor...
Chimerix, Inc.
Biomea Fusion, Inc.